HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours By Ogkologos - July 30, 2025 717 0 Facebook Twitter Google+ Pinterest WhatsApp Real-world experience from pan-tumour testing Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR EMA Recommends Extension of Indications for Tislelizumab July 24, 2025 Ground-breaking trial pilots new tests to detect lung cancer earlier June 16, 2021 Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced... October 11, 2024 Woman With Double Mastectomy Invents Breastfeeding Simulator For Breast Cancer Survivors November 15, 2019 Load more HOT NEWS New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers Dog Showers His Mom with Snuggles and Makes Her Laugh During... The most important cancer research stories of 2022 Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in...
